Astria Therapeutics (NASDAQ:ATXS) Rating Lowered to “Hold” at Jefferies Financial Group

Astria Therapeutics (NASDAQ:ATXS) was downgraded by analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have a $13.00 price objective on the biotechnology company’s stock, down from their previous price objective of $30.00. Jefferies Financial Group’s price target points to a potential upside of 11.97% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Evercore ISI reissued an “outperform” rating and set a $26.00 target price on shares of Astria Therapeutics in a research report on Wednesday, October 1st. Citigroup restated an “outperform” rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. JMP Securities raised their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 13th. HC Wainwright raised their price target on shares of Astria Therapeutics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $49.00 price target on shares of Astria Therapeutics in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

Astria Therapeutics Stock Up 37.1%

Astria Therapeutics stock opened at $11.61 on Tuesday. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.52. The company’s 50 day moving average price is $7.23 and its two-hundred day moving average price is $5.94. The stock has a market cap of $655.27 million, a P/E ratio of -5.78 and a beta of 0.43.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.04. On average, equities analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATXS. Farther Finance Advisors LLC grew its stake in Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,557 shares in the last quarter. Brooklyn Investment Group grew its stake in Astria Therapeutics by 1,079.6% in the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,957 shares in the last quarter. GAMMA Investing LLC grew its stake in Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares in the last quarter. Corton Capital Inc. purchased a new position in Astria Therapeutics in the 1st quarter valued at approximately $72,000. Finally, AlphaQuest LLC grew its stake in Astria Therapeutics by 100.9% in the 1st quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 7,139 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.